Most stock indexes ended the week lower as more weakness in the tech sector matched with an uncertain macroeconomic outlook. U.S. strikes on Iran and retaliatory drone attacks meant ongoing supply risks around the Strait of Hormuz. The technology sector was under pressure as companies with exposure to the AI trade pared. SK Hynix ( SKHYV ) American depositary receipts jumped 12.8% above their offe...
Most stock indexes ended the week lower as more weakness in the tech sector matched with an uncertain macroeconomic outlook. U.S. strikes on Iran and retaliatory drone attacks meant ongoing supply risks around the Strait of Hormuz. The technology sector was under pressure as companies with exposure to the AI trade pared. SK Hynix ( SKHYV ) American depositary receipts jumped 12.8% above their offering price after raising $26.5 billion in the largest-ever US listing by a foreign company. For the week, the S&P 500 ( SP500 ) and Nasdaq ( COMP:IND ) rose 0.7% and 1.4%, while Dow ( DJI ) booked a 1.1% fall. Investor attention is firmly fixed on the upcoming corporate earnings season. Across the Atlantic, the European equities ( STOXX ) ended the week 1.4% lower. In the week, London’s FTSE 100 ( UKX ) equities fell 1.5% while Germany ( DAX:IND ) and France ( CAC:IND ) markets slipped 2.8% and 2%, respectively. Major corporate news from Europe this week: Airbus ( EADSF ) ( EADSY ) lowered its 20-year industry-wide forecast for passenger aircraft demand by 1%, pointing to the Iran war and escalating trade tensions for knocking aviation's post-COVID rebound off course. UAE telecoms operator e& Group would sell its entire stake in Vodafone ( VOD ) to a company owned by French telecoms tycoon Xavier Niel for $5.95B, making him the company’s largest shareholder. British low-cost airline easyJet ( EJTTF ) agreed in principle to a £5.7B takeover offer from Apollo Global Management's Apollo Management X. AstraZeneca’s ( AZN ) gene-silencing therapy Wainua, developed with Ionis Pharmaceuticals, failed a late-stage clinical trial aimed at reducing heart complications in patients with a rare cardiac condition. The Asia-Pacific markets China's consumer inflation eased to a three-month low in June, falling short of market expectations. The World Bank expects China's economic growth to slow over the coming years as weak domestic demand, a prolonged property downturn, and softer expo...
Artificial intelligence (AI) has a major bottleneck, and it isn't limited to chips, servers, or memory. Estimates suggest that trillions in investment will be needed to build the power infrastructure to support data centers in the coming years. That's good news for investors who feel like they missed the early innings of the AI bull market. AI is still in its infancy compared to what it could beco...
Artificial intelligence (AI) has a major bottleneck, and it isn't limited to chips, servers, or memory. Estimates suggest that trillions in investment will be needed to build the power infrastructure to support data centers in the coming years. That's good news for investors who feel like they missed the early innings of the AI bull market. AI is still in its infancy compared to what it could become over the next 30 years, and companies that supply the power and cooling behind the scenes could be positioned for years of growth. Two leaders in this space, Vertiv Holdings (NYSE: VRT) and GE Vernova (NYSE: GEV) , have already seen their share prices soar 102% and 65%, respectively, this year. Here's why they should continue to outperform the market through the end of the decade, and likely beyond. Continue reading
Sen. Lindsey Graham (R-SC) talks to reporters outside of the West Wing of the White House on February 28, 2025 in Washington, DC. Following a heated exchange between Ukrainian President Volodymyr Zelensky and U.S. President Donald Trump in the Oval Office, Graham told reporters that Zelensky should resign. Chip Somodevilla | Getty Images News | Getty Images Sen. Lindsey Graham 's death stands to s...
Sen. Lindsey Graham (R-SC) talks to reporters outside of the West Wing of the White House on February 28, 2025 in Washington, DC. Following a heated exchange between Ukrainian President Volodymyr Zelensky and U.S. President Donald Trump in the Oval Office, Graham told reporters that Zelensky should resign. Chip Somodevilla | Getty Images News | Getty Images Sen. Lindsey Graham 's death stands to scramble an array of Republican policy efforts, as Congress loses one of its top White House whisperers and coalition builders. Graham, R-S.C., who died at 71, was a titan of the Senate whose close relationship with President Donald Trump helped the upper chamber broker numerous deals and secure aid for allies such as Ukraine. Graham, who chaired the Senate Budget Committee, was integral to passing Trump's marquee reconciliation tax-and-spending law, known as the "one big, beautiful bill." He also served on the Appropriations, Judiciary, and Environment and Public Works Committees and was known to work across the aisle on policy issues. Graham's death comes as the Senate works to advance many of Trump's priorities before heading into a tough midterm election in November, and his passing is likely to complicate those efforts. Included in the long list of unfinished business is the SAVE America Act, Trump's sought-after voter-ID bill; a third reconciliation bill to address affordability and replenish the military; and the confirmation of Attorney General nominee Todd Blanche. SAVE America Act Graham was a staunch advocate for the SAVE America Act , Trump's laundry list bill to require voter ID and proof of citizenship to vote, along with several other White House priorities. Trump has been almost singularly focused on the bill, despite its steep odds of becoming law. Trump, in a Sunday call on NBC's "Meet the Press," lamented that the SAVE America Act will be harder to pass without Graham's support. "This is a big blow to the Save America Act, let me tell you," Trump said. "He...
Mark Schoenberg, Chief Medical Officer, sold 10,000 ordinary shares of UroGen Pharma Ltd. (NASDAQ:URGN) on July 9, 2026, for a total value of $400,000, according to an SEC Form 4 filing . UroGen Pharma is a commercial-stage biotechnology company with a $2 billion market capitalization, demonstrating significant growth momentum with a one-year stock appreciation of 191.31%. The company has achieved...
Mark Schoenberg, Chief Medical Officer, sold 10,000 ordinary shares of UroGen Pharma Ltd. (NASDAQ:URGN) on July 9, 2026, for a total value of $400,000, according to an SEC Form 4 filing . UroGen Pharma is a commercial-stage biotechnology company with a $2 billion market capitalization, demonstrating significant growth momentum with a one-year stock appreciation of 191.31%. The company has achieved meaningful revenue scale at $140.5 million TTM while maintaining a focused pipeline strategy centered on proprietary drug delivery technologies for underserved oncology indications. UroGen's competitive advantage derives from its proprietary RTGel platform technology and its established commercial infrastructure for specialty cancer therapeutics, positioning the company as a differentiated player in the niche urothelial cancer treatment market. First, it’s important to note that this was the final trade in a 10b5-1 plan Schoenberg set almost a year ago, so the timing was locked in long before Schoenberg could know how the firm was necessarily going to be performing. He still holds nearly 120,000 shares worth close to $4.8 million, and a chief medical officer keeping a stake that size while the company's newest drug is inflecting isn't sending any signal about the science. The launch of Zusduri, UroGen’s new bladder cancer therapy, is what matters here, and it's going well. UroGen's first quarter revenue jumped 152% to $51 million, as a result of the launch, which brought in $29.2 million and more than doubled quarter over quarter after a permanent insurance billing code kicked in. CEO Liz Barrett called January's J-code "a major inflection point," and unique prescribers jumped to 256 from 102 in a single quarter. More recently, the firm announced that the FDA cleared its investigational new drug application for UGN-501, enabling a planned Phase 1 study in patients with non-muscle invasive bladder cancer. It’s expected to begin in the fourth quarter. Continue reading
John Moore/Getty Images News The United States launched fresh strikes against Iran on Sunday after Tehran attacked a container ship in the Strait of Hormuz, setting it ablaze and leaving one crew member missing, the Associated Press reported. Iran retaliated with missile and drone attacks targeting several countries hosting U.S. forces, including Bahrain, Kuwait, Qatar, Jordan and Oman, escalating...
John Moore/Getty Images News The United States launched fresh strikes against Iran on Sunday after Tehran attacked a container ship in the Strait of Hormuz, setting it ablaze and leaving one crew member missing, the Associated Press reported. Iran retaliated with missile and drone attacks targeting several countries hosting U.S. forces, including Bahrain, Kuwait, Qatar, Jordan and Oman, escalating tensions around one of the world's most important energy chokepoints. U.S. forces later conducted additional strikes on missile systems, air defenses and Revolutionary Guard naval assets near the strait, according to a U.S. official. Iran's state media reported explosions near military sites around Qeshm Island and Bandar Abbas. For investors, the latest escalation raises fresh concerns about the security of the Strait of Hormuz, through which roughly one-fifth of global oil and liquefied natural gas trade typically passes. While shipping traffic has continued at reduced levels and oil prices remain below wartime peaks, any prolonged disruption could increase energy costs, pressure global supply chains and complicate markets already monitoring the fragile U.S.-Iran ceasefire talks. The attacks come as Washington and Tehran approach the midpoint of a 60-day interim agreement intended to pave the way for a permanent end to the conflict. Disputes over control of the strait have emerged as a major obstacle to negotiations. The United Nations expressed alarm over the latest violence. Secretary-General António Guterres was "deeply concerned by the serious escalation," according to a statement. President Donald Trump defended the U.S. campaign, telling NBC's "Meet the Press": "We bombed the hell out of them last night." The U.S. military said it struck about 140 targets, including missile and drone launch sites, ammunition depots and communications facilities, describing the operation as an effort to reduce Iran's ability to threaten commercial shipping. Iran, meanwhile, maintain...
Key PointsFormer CEO Shawn Morris sold 135,498 shares on June 30 and July 1, 2026, generating proceeds of ~$3.57 million at a weighted average price around $26.32 per share.
Key PointsFormer CEO Shawn Morris sold 135,498 shares on June 30 and July 1, 2026, generating proceeds of ~$3.57 million at a weighted average price around $26.32 per share.
Key PointsThe entity acquired 610,291 shares at a weighted average price of $11.82 per share, representing a total capital commitment of about $7.2 million.
Key PointsThe entity acquired 610,291 shares at a weighted average price of $11.82 per share, representing a total capital commitment of about $7.2 million.
Navitas Semiconductor (NVTS) built its 2026 comeback around AI data centers, and those who bought into its business are now watching it fight a major legal battle. NVTS shares had climbed sharply this year because of the company's shift into high-power chips for AI server racks. However, ...
Navitas Semiconductor (NVTS) built its 2026 comeback around AI data centers, and those who bought into its business are now watching it fight a major legal battle. NVTS shares had climbed sharply this year because of the company's shift into high-power chips for AI server racks. However, ...